Pharmacy Times®
Specialty Pharmacy Times
  • Top 10 Trends in Specialty Pharmacy
  • OIG Releases Report on Medicare Part B Drug Price Data
  • Valued Services from Specialty Pharmacy: A Manufacturers Perspective
  • Who Is the Customer in Specialty?
  • How Will Specialty Pharmacy Be Affected By Cost Containment?
  • Specialty Pharmacies Help Patients Manage Immune Globulin Care
Early Lung Cancer Treatment Affected by Race, Insurance Status
Davy James, Associate Editor
Study finds African Americans and Hispanics significantly less likely to be treated with radiation.
Plague Outbreak in Madagascar
Michael R. Page, PharmD, RPh
A total of 40 deaths have been recorded in the latest outbreak of bubonic and pneumonic plague in Madagascar.
Anti-HIV Drugs May Cause Long Term Damage to Fetal Heart Development
Davy James, Associate Editor
Study finds treatment that prevents transmission of virus from mother to child leads to reduced heart performance.
Cyramza by Eli Lilly
Michael R. Page, PharmD, RPh
Cyramza (ramucirumab) was approved for treatment of patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma after disease progression.
Zontivity by Merck and Co, Inc
Michael R. Page, PharmD, RPh
The FDA has approved Zontivity (voraxapar) for prevention of thrombotic cardiovascular events in patients with peripheral artery disease or a history of myocardial infarction.
Featured Video
Armada and Specialty Pharmacy
Thomas Cohn, chief strategy officer at Armada Health Care, discusses the services Armada provides for specialty pharmacies.
Industry Guide
We've created this Industry Guide with close to 300 companies and organizations as a one-stop guide for industry stakeholders in the specialty pharmacy space.
Current Issue
Conference Calendar
â—„        November 2014        â–º
Featured Company Profile
Pharmacy Times
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright Pharmacy Times 2006-2013
Intellisphere, LLC. All Rights Reserved.